As market conditions stabilize and capital begins to re-engage, contract development and manufacturing organizations (CDMOs) are emerging as central drivers of value creation across the MedTech ecosystem. In 2026, the convergence of financial clarity, strategic repositioning, and platform scale ambition is expected to redefine how OEMs and investors approach growth, partnerships, and M&A in the sector. After several years of market volatility and uneven deal activity, MedTech CDMO M&A is approaching a turning point. Stabilizing public markets, improving visibility on financing costs, and significant levels of uninvested capital are setting the stage for renewed transaction momentum in 2026.
Read the full article: CDMO Platforms Will Be the Central Arena for MedTech M&A in 2026 //
Source: https://www.mondaq.com/unitedstates/life-sciences-biotechnology-nanotechnology/1749798/cdmo-platforms-will-be-the-central-arena-for-medtech-ma-in-2026